CERo Therapeutics receives Nasdaq delisting notice for MVLS non-compliance; appeals hearing requested

CERO THERAPEUTICS HOLDINGS, INC.

Nasdaq notified CERo on Oct 30, 2024 that it failed to regain compliance with $50M MVLS requirement by Oct 29 cure period.
Delisting scheduled for Nov 8, 2024 unless stayed by appeal; CERo requested hearing on Oct 31, 2024.
Hearing request automatically stays suspension of common stock trading pending panel decision.
Company intends to present a compliance plan covering both MVLS and prior bid-price deficiency disclosed Oct 25, 2024.
No assurance of favorable panel decision or ability to regain/maintain Nasdaq compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.